Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
Trial ID or NCT#
NCT00373347
Status
RECRUITING
Purpose
The aim of the study is to see if there any changes in the quality of life for patients that are undergoing radical prostatectomy.
Official Title
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
- Patients diagnosed with liver cancer based on biopsy or serum AFP level, associated with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI. - Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or nodular hyperplasia. - Patients with hepatitis B or hepatitis C viral infections not associated with liver cancer.
Exclusion Criteria:
- Patients will be excluded if, upon looking through their medical records, information required for data analysis are missing.
Investigator(s)
Samuel So, MD
Surgical oncologist,
Liver surgeon,
General surgeon
Lui Hac Minh Professor in the School of Medicine
Contact us to find out if this trial is right for you.
CONTACT
Mei-Sze Chua
(650) 724-3525
View on ClinicalTrials.gov
About this Clinical Trial
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
Your Message Will Go To
Mei-Sze Chua650-724-3525